

2015 Cancer Registry Data Review

In 2015 Mon General added 772 new cancer patients to our data base. 658 of these were diagnosed and/or treated first course here (analytic). Highlights of the class of case are: 311 patients received diagnosis and all treatment at Mon General, 83 were diagnosed here with part of treatment here and part of treatment elsewhere, 123 were diagnosed elsewhere and had all treatment here, 72 were diagnosed elsewhere and had part of their treatment here, and 17 were diagnosed in a staff physician's office and had all or part of 1st course treatment here. Only 52 were diagnosed here and received all of their treatment elsewhere.

Of the 658 analytic cases 197 cases were in the age group of 60-69, 155 were 70-79, 134 were 50-59, 83 were 80-89 and 50 were 40-49 years of age at the time of diagnosis. Also of interest this year was 21 patients were 30-39 years of age, 13 were over 90, and 5 were 0-29. The mean age for this group was 65.

66% of cases were female and 34% male. This disparity is due to the fact that three of our top 5 sites were primarily female cancers, providing first course treatment to 118 uterine, 80 breast (female), and 42 ovarian cancers. Lung cancer came in the number 3 spot with 73 cases and colon number 4 with 50 cases. This made up our top 5 sites for 2015.

When comparing the top 5 sites AJCC stage at diagnosis we see that 174 cases were diagnosed at stage I, 70 at stage II, 86 at stage III and 73 at stage IV.

Rounding out number 6 thorough 10 of our top sites in 2015 were: 39 prostate, 30 bladder, 29 thyroid, 25 hematopoietic, and 21 kidney cases. The top 10 sites comprised 507 out of our 658 analytic cases.

The top counties serviced by our cancer center in 2015 were Monongalia 213, Marion 105, Preston 89, Harrison 52, Randolph 18, Taylor 18, and Mineral and Ohio counties each served 16 patients. Also of interest, 45 of our patients reside in PA, 45 in Maryland, and 19 in Ohio.

The Zelda Stein Weiss Cancer Center at Mon General Hospital underwent the Commission on Cancer, Comprehensive Cancer Program Accreditation Survey on August 24, 2016. Results at this time are 3 year approval with contingency, pending further resolution.